Resilience Expands Biologics Mfg with New Facilities

By Miranda Greenberg -

April 1, 2021

Resilience, a recently launched manufacturing and technology company for biologics and advanced therapies, has acquired two commercial manufacturing facilities in North America, including a facility from Sanofi.

Resilence was launched in November 2020 with initial capital of $800 million with a specific focus on manufacturing innovation, including for new modalities. Its executive leadership includes Patrick Yang, Ph.D, Vice Chairman, Resilience, and former Executive Vice President and Global Head of Technical/Product Operations, Roche/Genentech, and Rahul Singhvi, SC.D., M.B.A, Co-Founder, CEO, and Director, and former Chief Operating Officer of Takeda’s Vaccine business, where he was responsible for worldwide vaccine CMC and manufacturing operations.  Before Takeda, Dr. Singhvi was President and CEO of Novavax, a Gaithersburg, Maryland-based vaccine company, from 2005 to 2011.

The acquired facilities include a 310,000-square-foot plant in Boston, Massachusetts, purchased from Sanofi, and in a 136,000-square-foot plant in Mississauga, Ontario, Canada, purchased in a separate transaction. Both facilities currently produce commercial products, and Resilience is planning further investment at the facilities. The company has offered employment to the existing plant staff and intends to add more jobs at each facility.

As part of its agreement with Sanofi, Resilience will continue to manufacture a marketed product at the Boston site. The facility plan includes a build-out to facilitate multi-modality manufacturing and quality laboratories. The facility offers multiple 2,000-L bioreactors capacity and multiple downstream processing trains, with investment in additional capabilities to come.

This is currently the largest of several facilities in Resilience’s biologics and advanced therapeutics manufacturing network. The company says it plans to acquire and develop other sites in the US this year (2021).

The facility in Mississauga, Ontario, provides upstream and downstream processing and aseptic fill–finish,

The addition of the two facilities boosts the company’s total capacity under management to more than 750,000 square feet.

Source: Resilience